Ventyx Biosciences (NASDAQ:VTYX) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Ventyx Biosciences (NASDAQ:VTYX) posted its quarterly earnings data on Thursday. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.13, Zacks reports.

Ventyx Biosciences Stock Performance

Shares of VTYX stock opened at $1.58 on Friday. Ventyx Biosciences has a 52-week low of $1.41 and a 52-week high of $11.48. The stock has a market cap of $111.72 million, a PE ratio of -0.67 and a beta of 0.52. The firm’s 50 day moving average price is $1.97 and its two-hundred day moving average price is $2.15.

Analyst Ratings Changes

A number of brokerages recently weighed in on VTYX. HC Wainwright reissued a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th. Oppenheimer reissued an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th.

Insider Buying and Selling at Ventyx Biosciences

In other news, insider John Nuss sold 21,119 shares of Ventyx Biosciences stock in a transaction on Friday, December 27th. The shares were sold at an average price of $2.36, for a total transaction of $49,840.84. Following the transaction, the insider now directly owns 464,582 shares of the company’s stock, valued at $1,096,413.52. This trade represents a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Sheila Gujrathi purchased 130,000 shares of Ventyx Biosciences stock in a transaction dated Monday, December 23rd. The shares were purchased at an average cost of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the transaction, the director now owns 130,000 shares of the company’s stock, valued at approximately $300,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 18.18% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.